Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

NCT04739202 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma
Metastatic Gastric Cancer
Metastatic Adenocarcinoma
Advanced Gastric Carcinoma

Interventions

DRUG: Atezolizumab + Ipatasertib
DRUG: Atezolizumab + Bevacizumab

Sponsor

Hospices Civils de Lyon